Chronic Kidney Disease (CKD) – High-Yield Study Guide for Medical Students
Definition
Chronic Kidney Disease (CKD) is defined as abnormalities of kidney structure or function present for >3 months, with implications for health. It is typically characterized by either:
- Decreased GFR: eGFR <60 mL/min/1.73 m² for >3 months, with or without other evidence of kidney damage.
- Markers of kidney damage: e.g., albuminuria (ACR ≥30 mg/g), urine sediment abnormalities, electrolyte abnormalities due to tubular disorders, structural abnormalities on imaging, or history of kidney transplantation.
CKD is categorized by GFR (G1–G5) and albuminuria (A1–A3), which together stratify risk of progression and complications.[10](https://europepmc.org/article/MED/41805824)
Epidemiology
CKD is a major global public health problem with increasing prevalence, driven primarily by aging populations and rising rates of diabetes and hypertension. It significantly increases the risk of cardiovascular disease, hospitalization, and all-cause mortality.[10](https://europepmc.org/article/MED/41805824)
- Prevalence is highest in older adults and in individuals with diabetes, hypertension, and obesity.
- Many patients remain asymptomatic until advanced stages, leading to underdiagnosis and late referral to nephrology.
- CKD contributes substantially to the global burden of cardiovascular disease through shared risk factors and overlapping pathophysiology, including chronic inflammation.[10](https://europepmc.org/article/MED/41805824)
Pathophysiology
CKD is the final common pathway of diverse kidney insults (e.g., diabetic nephropathy, hypertensive nephrosclerosis, glomerulonephritis) leading to progressive nephron loss. The remaining nephrons undergo adaptive changes that become maladaptive over time.
- Nephron loss and hyperfiltration: Surviving nephrons increase single-nephron GFR, leading to glomerular hypertension, capillary wall stress, and further nephron injury.
- Fibrosis and structural remodeling: Chronic injury drives activation of fibroblasts and myofibroblasts, ECM deposition, and interstitial fibrosis, resulting in irreversible damage.
- Disordered mineral metabolism: Reduced nephron mass impairs phosphate excretion and vitamin D activation. Bone-derived hormones such as fibroblast growth factor 23 (FGF23) increase early to enhance phosphaturia and suppress 1,25(OH)2D, but chronically contribute to left ventricular hypertrophy and vascular dysfunction.[1](https://pubmed.ncbi.nlm.nih.gov/41833603/)
- Secondary/tertiary hyperparathyroidism: Hyperphosphatemia, hypocalcemia, and low calcitriol stimulate parathyroid hormone (PTH). Chronic stimulation leads to parathyroid hyperplasia and autonomous PTH secretion (tertiary hyperparathyroidism), often requiring parathyroidectomy in advanced kidney replacement therapy patients.[7](https://europepmc.org/article/MED/41809842)
- Chronic inflammation: Persistent low-grade inflammation characterized by elevated interleukin-6 and C-reactive protein links CKD to accelerated atherosclerosis, vascular calcification, and heart failure.[10](https://europepmc.org/article/MED/41805824)
These mechanisms converge to cause progressive reduction in GFR and systemic complications affecting cardiovascular, skeletal, hematologic, endocrine, and immune systems.
Clinical Presentation
Early CKD is often asymptomatic and discovered via routine lab screening (elevated creatinine, albuminuria). Symptoms typically appear in more advanced stages.
- General: Fatigue, weakness, decreased exercise tolerance, anorexia, weight loss.
- Fluid & electrolytes: Peripheral edema, pulmonary congestion, hypertension; hyperkalemia in advanced disease.
- Uremic symptoms: Nausea, vomiting, metallic taste, pruritus, restless legs, sleep disturbance, cognitive changes, pericarditis (chest pain, friction rub) in severe uremia.
- Hematologic: Normocytic normochromic anemia (EPO deficiency), increased bleeding tendency (platelet dysfunction).
- Bone/mineral: Bone pain, fractures, skeletal deformities, vascular and soft tissue calcifications due to CKD–mineral and bone disorder (CKD–MBD).[1](https://pubmed.ncbi.nlm.nih.gov/41833603/)
- Cardiovascular: Resistant hypertension, LVH, heart failure, accelerated atherosclerosis and vascular calcification.[10](https://europepmc.org/article/MED/41805824)
- Reproductive: Menstrual irregularities, reduced fertility; reproductive function often improves after kidney transplantation.[5](https://pubmed.ncbi.nlm.nih.gov/41808638/)
Diagnosis
Diagnosis is based on evidence of kidney damage and/or reduced kidney function persisting >3 months.
Initial Evaluation
- History and examination: Risk factors (diabetes, hypertension, autoimmune disease, nephrotoxin exposure), family history, urinary symptoms, systemic features.
- Serum tests: Creatinine, BUN, electrolytes, bicarbonate, calcium, phosphate, PTH, albumin, lipid profile, HbA1c in diabetics, inflammatory markers as clinically indicated.[10](https://europepmc.org/article/MED/41805824)
- eGFR calculation: Using creatinine-based equations; trend over time is more informative than single values.
- Urine testing: Urinalysis (protein, blood, sediment), urine albumin-to-creatinine ratio (ACR) to quantify albuminuria.
- Imaging: Renal ultrasound to assess size, echogenicity, and structural abnormalities (e.g., obstruction, cysts). Advanced techniques like diffusion tensor imaging (DTI) can noninvasively characterize microstructural changes in pediatric CKD, helping early detection of dysfunction.[3](https://pubmed.ncbi.nlm.nih.gov/41824047/)
CKD Staging (KDIGO Framework)
GFR Categories (G1–G5)
- G1: ≥90 mL/min/1.73 m² (normal or high; requires other evidence of kidney damage).
- G2: 60–89 (mildly decreased; with other evidence of damage).
- G3a: 45–59 (mild-to-moderately decreased).
- G3b: 30–44 (moderately-to-severely decreased).
- G4: 15–29 (severely decreased).
- G5: <15 (kidney failure; often requires kidney replacement therapy).
Albuminuria Categories (A1–A3)
- A1: ACR <30 mg/g (normal to mildly increased).
- A2: 30–300 mg/g (moderately increased, formerly microalbuminuria).
- A3: >300 mg/g (severely increased, formerly macroalbuminuria).
GFR and albuminuria categories are combined in a heat map to stratify risk for CKD progression, cardiovascular events, and mortality.[10](https://europepmc.org/article/MED/41805824)
Management
Management aims to slow progression, treat complications, and reduce cardiovascular risk, with timely preparation for kidney replacement therapy when indicated.
General Principles
- Identify and treat the underlying cause: Optimize glycemic control in diabetes, manage hypertension, treat glomerulonephritides, relieve obstruction, discontinue nephrotoxins.
- Blood pressure control: Typically target <130/80 mmHg (individualized). ACE inhibitors or ARBs are first-line for albuminuric CKD due to renoprotective and antiproteinuric effects.
- Glycemic control: In diabetics, aim for individualized HbA1c (often around 7%), with attention to hypoglycemia risk in advanced CKD.
- Lifestyle modification: Sodium restriction, weight management, smoking cessation, regular physical activity.
Cardiorenal Protection and Inflammation
- RAAS blockade: ACE inhibitors/ARBs reduce intraglomerular pressure and proteinuria and improve cardiovascular outcomes.
- Mineralocorticoid receptor antagonists (MRAs): Agents such as spironolactone, eplerenone, and newer nonsteroidal MRAs (e.g., finerenone) provide additional reduction in albuminuria and cardiovascular events but require careful monitoring for hyperkalemia.[4](https://pubmed.ncbi.nlm.nih.gov/41818046/)
- Inflammation targeting: Elevated IL-6 and CRP are associated with increased CVD risk in CKD; emerging therapies aim to attenuate this residual inflammatory risk, complementing standard risk factor modification.[10](https://europepmc.org/article/MED/41805824)
Management of CKD–Mineral and Bone Disorder (CKD–MBD)
- Control serum phosphate with dietary restriction and phosphate binders.
- Correct vitamin D deficiency and manage PTH levels with vitamin D analogues and calcimimetics as appropriate.
- Parathyroidectomy may be required in refractory renal hyperparathyroidism, especially in patients on long-term dialysis, improving biochemical control and bone pain.[7](https://europepmc.org/article/MED/41809842/)
Anemia Management
- Evaluate iron status; give oral or IV iron to correct deficiency.
- Use erythropoiesis-stimulating agents (ESAs) in symptomatic anemia or when hemoglobin is persistently low despite iron repletion, targeting a hemoglobin range that balances symptom relief and thrombotic risk.
Preparation for Kidney Replacement Therapy (KRT)
As patients approach advanced CKD (G4–G5), planning for KRT is essential.
- Modality discussion: Hemodialysis, peritoneal dialysis, or kidney transplantation.
- Hemodialysis access: Prefer autogenous arteriovenous fistulas over prosthetic grafts and tunneled catheters due to superior patency and lower infection risk; complications include stenosis, thrombosis, aneurysm, and infection, requiring meticulous surveillance and management.[6](https://europepmc.org/article/MED/41738845)
- Transplantation: Living donor kidney transplantation offers superior survival and quality of life compared to dialysis. Programs focusing on education, donor outreach, and reducing logistical barriers can significantly increase access to living donor transplantation.[9](https://europepmc.org/article/MED/41641402)
- Post-transplant: Reproductive potential often improves, allowing consideration of pregnancy under specialized care, though residual fertility challenges and the teratogenicity of some immunosuppressants require careful planning.[5](https://pubmed.ncbi.nlm.nih.gov/41808638/)
Key Clinical Pearls
- 1. CKD is often silent: Screen high-risk groups (diabetes, hypertension, CVD, family history) with eGFR and urine ACR; early detection allows timely intervention.
- 2. Use GFR + albuminuria: Both parameters are needed to accurately stage CKD and predict risk; a patient with G2A3 may be at higher risk than G3aA1.
- 3. RAAS blockade and MRAs are reno- and cardioprotective: They reduce proteinuria and cardiovascular events but require monitoring for hyperkalemia and changes in kidney function.[4](https://pubmed.ncbi.nlm.nih.gov/41818046/)
- 4. Chronic inflammation is a key driver of CVD in CKD: Elevated IL-6 and CRP are not just markers but contributors to residual cardiovascular risk; management must address both classic risk factors and inflammatory burden.[10](https://europepmc.org/article/MED/41805824)
- 5. Disordered mineral metabolism begins early: FGF23 rises before overt hyperphosphatemia, helping maintain phosphate balance but also contributing to LVH and vascular dysfunction.[1](https://pubmed.ncbi.nlm.nih.gov/41833603/)
- 6. CKD–MBD needs proactive management: Target phosphorus, calcium, vitamin D, and PTH; consider parathyroidectomy in refractory tertiary hyperparathyroidism, particularly in long-term dialysis patients.[7](https://europepmc.org/article/MED/41809842/)
- 7. Vascular access planning is critical: Early referral for AV fistula creation improves dialysis outcomes; monitor access for stenosis and thrombosis to prevent access failure.[6](https://europepmc.org/article/MED/41738845)
- 8. Transplant is the preferred KRT when feasible: Living donor kidney transplantation offers the best long-term survival and quality of life; dedicated programs can overcome many barriers to donor identification and evaluation.[9](https://europepmc.org/article/MED/41641402)
- 9. CKD affects fertility and pregnancy: Counsel patients about reproductive health; kidney transplantation often restores fertility, but pregnancies require specialized multidisciplinary management.[5](https://pubmed.ncbi.nlm.nih.gov/41808638/)
- 10. Think beyond the kidneys: CKD is a systemic disease involving inflammation, cardiovascular dysfunction, bone disease, anemia, and endocrine alterations. Comprehensive, multidisciplinary care is required to optimize outcomes.[1](https://pubmed.ncbi.nlm.nih.gov/41833603/), [10](https://europepmc.org/article/MED/41805824)